BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cotter TG, Jensen DM. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy. Drug Des Devel Ther 2019;13:2565-77. [PMID: 31534310 DOI: 10.2147/DDDT.S172512] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Shamsi A, Mohammad T, Anwar S, AlAjmi MF, Hussain A, Rehman MT, Islam A, Hassan MI. Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy. Biosci Rep 2020;40:BSR20201256. [PMID: 32441299 DOI: 10.1042/BSR20201256] [Cited by in Crossref: 59] [Cited by in F6Publishing: 32] [Article Influence: 29.5] [Reference Citation Analysis]
2 Cho H, Suematsu H, Oyala PH, Peters JC, Fu GC. Photoinduced, Copper-Catalyzed Enantioconvergent Alkylations of Anilines by Racemic Tertiary Electrophiles: Synthesis and Mechanism. J Am Chem Soc . [DOI: 10.1021/jacs.1c12749] [Reference Citation Analysis]
3 Green V, Roytman M, Komatsu H. Treatment-Resistant Hepatitis C Viral Infection: A Case Report and Literature Review. Case Reports in Hepatology 2022;2022:1-5. [DOI: 10.1155/2022/3556780] [Reference Citation Analysis]
4 Kumar S, Singh B, Kumari P, Kumar PV, Agnihotri G, Khan S, Kant Beuria T, Syed GH, Dixit A. Identification of multipotent drugs for COVID-19 therapeutics with the evaluation of their SARS-CoV2 inhibitory activity. Comput Struct Biotechnol J 2021;19:1998-2017. [PMID: 33841751 DOI: 10.1016/j.csbj.2021.04.014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Miao M, Jing X, De Clercq E, Li G. Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy. Drug Des Devel Ther 2020;14:2759-74. [PMID: 32764876 DOI: 10.2147/DDDT.S254754] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
6 Denel-bobrowska M, Olejniczak AB. Non-nucleoside structured compounds with antiviral activity—past 10 years (2010–2020). European Journal of Medicinal Chemistry 2022;231:114136. [DOI: 10.1016/j.ejmech.2022.114136] [Reference Citation Analysis]
7 Mangia A, Scaglione F, Toniutto P, Pirisi M, Coppola N, Di Perri G, Alvarez Nieto G, Calabrese S, Hernandez C, Perrone V, Degli Esposti L, Fagiuoli S. Drug-Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study. Int J Environ Res Public Health 2021;18:7144. [PMID: 34281080 DOI: 10.3390/ijerph18137144] [Reference Citation Analysis]
8 Bulankina AV, Richter RM, Welsch C. Regulatory Role of Phospholipids in Hepatitis C Virus Replication and Protein Function. Pathogens 2022;11:102. [DOI: 10.3390/pathogens11010102] [Reference Citation Analysis]